ArticleESMO open2018
Targeted therapy in cervical cancer.
Article in ESMO open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Changes in EGFR activity following CRISPR/Cas9-editing of the EGF binding domain.Scientific reports · 2026Article
- Isolation and quantification of polyphenolics, exploration of antioxidant, cytotoxicity, and wound healing activities of Pithecellobium dulce (Roxb.) Benth.Scientific reports · 2026Article
- Unveiling the ZNF384-INTS13-hnRNPC axis as a therapeutic vulnerability in cervical cancer.Cell death & disease · 2025Article
- PRDM1-driven SLC30A9 overexpression contributes to the malignant phenotype of cervical cancer cells via promoting mitochondrial hyperfunction.Cell death & disease · 2025Article
- Prognostic value of combining nutritional inflammatory index trajectories and tumor characteristics in cervical cancer.BMC women's health · 2025Article
- Patient willingness to pay and preference for cervical cancer treatments among middle- and low-income populations in Xinjiang.Journal of patient-reported outcomes · 2025Article
- Gap junction protein beta 5 interacts with Gαi3 to promote Akt activation and cervical cancer cell growth.Cell death & disease · 2025Article
- Mediation of Ethnic Disparity in the 5-Year Mortality of Cervical Cancer Patients in the US, 2001-2019.Healthcare (Basel, Switzerland) · 2025Article
- Long noncoding RNAs involved in therapeutic response: implications for cervical cancer drug resistance.Frontiers in oncology · 2025Review
- PET CT Imaging with FDG in the Therapeutical Management of Locally Advanced Cervical Cancer Diagnosed in a 43-Year-Old Patient: Case Report and Review of the Literature.Biomedicines · 2025Article
- The TFRC as a prognostic biomarker and potential therapeutic target in cervical cancer: a preliminary study.Frontiers in oncology · 2025Article
- Extraction Optimization and Anti-Tumor Activity of Polysaccharides fromMarine drugs · 2024Article
- Efficacy and Safety of Atezolizumab as a PD-L1 Inhibitor in the Treatment of Cervical Cancer: A Systematic Review.Biomedicines · 2024Review
- Betulinic acid induces apoptosis of HeLa cells via ROS-dependent ER stress and autophagy in vitro and in vivo.Journal of natural medicines · 2024Article
- The Role of Lymph Node Downstaging Following Neoadjuvant Treatment in a Group of Patients with Advanced Stage Cervical Cancer.Medicina (Kaunas, Lithuania) · 2024Article
- Review
- Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment.Cancers · 2024Article
- Gold nanoparticles (AuNPs) decrease the viability of cervical cancer cells by inducing the BAX gene and activating antioxidant enzymes.Molecular biology reports · 2024Article
- Interplay between reactive oxygen species and ERK activation in cervical cancer cells.Frontiers in cell and developmental biology · 2024Article
- LKB1/STK11 Tumor Suppressor Reduces Angiogenesis by Directly Interacting with VEGFR2 in Tumorigenesis.Biomolecules & therapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer continues to be a common cancer in women worldwide, especially in less developed regions where advanced stage presentations are common. Addition of bevacizumab to cytotoxic chemotherapy has been the only notable recent advance in the treatment of recurrent and metastatic cervical cancer. Outcomes in patients with locally advanced disease have also plateaued after meaningful gains were achieved with concomitant chemoradiation treatment. Recently, progress has been made in understanding the molecular aberrations in cervical cancer and new therapeutic modalities are emerging, including immune checkpoint inhibitors, therapeutic vaccines, antibody-drug conjugates, and others. In this review we will discuss the data and potential utility of these approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.